🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ULTRA-high-risk Surveillance to Avoid Future Events: the ULTRA-SAFE Trial

RecruitingNAAges 40 Years - 75 YearsAllNational Taiwan University Hospital
NCT07378930 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The ULTRA-SAFE clinical trial is a prospective, randomized study designed to address the limitations of current "one-size-fits-all" colorectal cancer surveillance guidelines. While international standards recommend a three-year follow-up colonoscopy for all high-risk patients, data suggests that those with multiple advanced adenomas face a significantly higher recurrence risk (20%) compared to those with only low-risk adenomas (9%). To provide more personalized care, the trial compares a Standard Arm (colonoscopy at year three) against a FIT Arm, where participants undergo annual fecal immunochemical testing in years one and two. A positive FIT triggers an earlier colonoscopy, with the goal of reducing the 3-year prevalence of metachronous advanced colorectal neoplasms (meta-ACRN) from 20% to approximately 12.7%. The study has enrolled roughly 940 participants to statistically validate w

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age: Adults aged 40 to 75 years. 2. Initial Colonoscopy Findings: Detection and removal of at least two advanced adenomas during the baseline colonoscopy. 3. Adherence: Willingness to comply with the assigned screening protocol, including fecal immunochemical testing (FIT) and follow-up colonoscopies Exclusion Criteria: 1. Age: Individuals younger than 40 or older than 75 years. 2. High-Risk Predispositions: Patients with inflammatory bowel disease (IBD), Familial Adenomatous Polyposis (FAP), or a documented hereditary colorectal cancer syndrome (e.g., Lynch syndrome). 3. Cancer History: A history of colorectal cancer (excluding carcinoma in situ). 4. Contraindications: Patients for whom polypectomy is clinically inappropriate or unsafe. 5. Adenoma Count/Type: Failure to meet the requirement of at least two advanced adenomas during the initial colonoscopy. 7.Extensive Low-Risk Lesions: Presence of more than ten low-risk adenomas. 8.Pregnancy: Currently pregnant individuals.
💊

What it tests

  • Early triage using Fecal immunochemical test
📍

Where

4 sites
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital Hsinchu Branch
Hsinchu, Taiwan
Fu Jen Catholic University Hospital
New Taipei City, Taiwan
National Taiwan University Cancer Center
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy